PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20180815 142819
20170730 175904
DJI 0051
20180130 175323
20180202 160131
DJI 0025
  • Biosimilar Product Information
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-04 By FDA
  • Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 – present
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-04 By FDA
  • Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 57, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-04
  • TACHOSIL
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-09-04 By FDA
  • GDUFA Type II API DMF Payment Receipts Report
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-04 By FDA
  • Drug Trials Snapshots
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-04 By FDA
  • Drug Trials Snapshots: IBTROZI
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-04 By FDA
  • Patent Certifications and Suitability Petitions
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-04 By FDA
  • Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Date of authorisation: 22/07/2014, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-04
  • Human medicines European public assessment report (EPAR): Beyonttra, acoramidis, Date of authorisation: 10/02/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-04
  • Complex Innovative Trial Design Meeting Program
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-04 By FDA
  • Human medicines European public assessment report (EPAR): Eurartesim, piperaquine tetraphosphate,artenimol, Date of authorisation: 27/10/2011, Revision: 15, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-04
  • Human medicines European public assessment report (EPAR): Topotecan Hospira, topotecan, Date of authorisation: 09/06/2010, Revision: 21, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-04
  • Human medicines European public assessment report (EPAR): Skyclarys, omaveloxolone, Date of authorisation: 09/02/2024, Revision: 7, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-04
  • Human medicines European public assessment report (EPAR): Triumeq, abacavir,dolutegravir,lamivudine, Date of authorisation: 31/08/2014, Revision: 36, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-04
Older posts
Theme: Scaffold by Danny Cooper.